patent1b
Stephanie Arnett/MITTR | Envato
The first CRISPR cure might kick-start the next big patent battle
That’s a real nice CRISPR cure you have there. It would be a pity if anything happened to it.
Okay. Drop the tough-guy accent and toss the black fedora aside. But I do believe that similar conversations could be occurring now that a historic gene-editing cure is coming to market, as soon as this year.
By the middle of December, Vertex Pharmaceuticals, based in Boston, is expected to receive FDA approval to sell a revolutionary new treatment for sickle-cell disease that’s the first to use CRISPR to alter the DNA inside human cells. (Vertex has already received regulatory approval in the UK.)
